EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal
The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care giant Johnson & Johnson (NYSE: JNJ) and 5.5 million euros on Swiss drug major Novartis (NOVN: VX) over pay-for-delay deal.
The news comes just a day after the EC released its reports that problematic patent settlements had dropped to a low level in 2012, citing industry awareness of antitrust concerns (The Pharma Letter December 10).
In July 2005, the EC stated, the respective Dutch subsidiaries of J&J and Novartis concluded an anticompetitive agreement to delay the market entry of a cheaper generic version of the opioid pain-killer fentanyl in the Netherlands, in breach of European Union antitrust rules. Fentanyl is a pain-killer 100 times more potent than morphine. It is used notably for patients suffering from cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze